Rapid desensitization for hypersensitivity reactions to chemotherapy agents

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 4, 2006, Pages 271-277

  Castells, Mariana ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Smith Building ^*  (United States)

Author keywords

Carboplatin; Chemotherapy; Desensitization; Monoclonals; Platinums; Taxenes

Indexed keywords

CARBOPLATIN; DOCETAXEL; DOXORUBICIN; INFLIXIMAB; MONOCLONAL ANTIBODY; PACLITAXEL; PLATINUM DERIVATIVE; RITUXIMAB; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; TAXOID;

ABDOMINAL PAIN; ANAPHYLAXIS; BRADYCARDIA; BRONCHOSPASM; CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; DESENSITIZATION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DYSPNEA; FATTY ACID DESATURATION; FLUSHING; HUMAN; HYPERTENSION; HYPOTENSION; MAST CELL; MUSCULOSKELETAL PAIN; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SKIN CELL; SKIN TEST; TACHYCARDIA; THORAX PAIN; THROAT TIGHTNESS; TREATMENT OUTCOME; URTICARIA; VOMITING; IMMUNOLOGY; METHODOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DESENSITIZATION, IMMUNOLOGIC; DOXORUBICIN; DRUG HYPERSENSITIVITY; HUMANS; ORGANOPLATINUM COMPOUNDS; TAXOIDS;

EID: 33748466196     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000235900.57182.15     Document Type: Review

References (70)

1. Wendel G, Stark B, Jamison RB, et al. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med 1985; 312:1229-1232.
2. Sullivan TJ. Antigen-specific desensitization of patients allergic to penicillin. J Allergy Clin Immunol 1982; 69:500-508.
3. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003; 24:253-262.
4. O'Donovan W, Klorfajn I. Sensitivity to penicillin: anaphylaxis and desensitization. Lancet 1946; 2:444.
5. Win PH, Brown H, Zankar A, et al. Rapid intravenous cephalosporin desensitization. J Allergy Clin Immunol 2005; 116:225-228.
6. Turvey SE, Cronin B, Arnold AD, Dioun AF. Antibiotic desensitization for the allergic patient: 5 years of experience and practice. Ann Allergy Asthma Immunol 2004; 92:426-432.
7. Schwartz LB, Metcalfe DD, Miller JS, et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987; 316:1622-1626.
8. Torres MJ, Blanca M, Fernandez J, et al. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy 2003; 58:961-972.
9. Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999; 17:1141.
10. Macglashan D, Miura K. Loss of syk kinase during IgE-mediated stimulation of human basophils. J Allergy Clin Immunol 2004; 114:1317-1324.
11. Odom S, Gomez G, Kovarova M, et al. Negative regulation of immunoglobulin E-dependent allergic responses by Lyn kinase. J Exp Med 2004; 199:1491-1502.
12. Kepley CL, Youssef L, Andrews RP, et al. Syk deficiency in nonreleaser basophils. J Allergy Clin Immunol 1999; 104 (2 Pt 1):279-284.
13. Malaviya R, Uckun FM. Role of STAT6 in IgE receptor/FcepsilonRI-mediated late phase allergic responses of mast cells. J Immunol 2002; 168:421-426.
14. Morales AR, Shah N, Castells M. Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol 2005; 94:575-580. STAT6 is found as a molecular target of rapid desensitizations in mast cells.
15. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8:1263-1268.
16. Wong JT, Ripple RE, Maclean JA, et al. Vancomycin hypersensitivity: synergism with narcotics and 'desensitization' by a rapid continuous intravenous protocol. J Allergy Clin Immunol 1994; 94 (2 Pt 1):189-194.
17. Markman M, Kennedy A, Webster K, et al. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000; 18:102-105.
18. Walker FE. Paclitaxel (TAXOL): side effects and patient education issues. Semin Oncol Nurs 1993; 9 (4 Suppl 2):6-10.
19. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998; 90:300-306.
20. Peereboom DM, Donehower RC, Eisenhauer EA, et al. Successful re-treatment with taxol after major hypersensitivity reactions [comment]. J Clin Oncol 1993; 11:885-890.
21. Markman M, Kennedy A, Webster K, et al. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol 1999; 125:427-429.
22. Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 2005; 96:824-829. Validation of a standard rapid desensitization protocol to treat anaphylactoid reactions to taxenes in 77 courses.
23. Price KS, Castells MC. Taxol reactions. Allergy Asthma Proc 2002; 23:205-208.
24. Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005; 99:393-399. Series of 255 courses of rapid desensitization for carboplatin, taxol, docetaxel and trastazumab as in-patients and first description of out-patients series.
25. Grosen E, Siitari E, Larrison E, et al. Paclitaxel hypersensitivity reactions related to bee-sting allergy. Lancet 2000; 355:288-289.
26. Micha JP, Goldstein BH, Birk CL, et al. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol 2006; 100:437-438. First demonstration that abraxene - a cremophor-free taxol - can be used in one patient with HSR to taxol.
27. Dizon DS, Dupont J, Anderson S, et al. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel - the Memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 2003; 91:584-590.
28. Bookman MA, Greer BE, Ozols RF. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. Int J Gynecol Cancer 2003; 13:735-740.
29. Kook H, Kim KM, Choi SH, et al. Life-threatening carboplatin hypersensitivity during conditioning for autologous PBSC transplantation: successful rechallenge after desensitization. Bone Marrow Transplant 1998; 21:727-729.
30. Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004; 95:370-376.
31. Zanotti KM, Rybicki LA, Kennedy AW, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 2001; 19:3126-3129.
32. Markman M, Zanotti K, Peterson G, et al. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003; 21:4611-4614.
33. Sliesoraitis S, Chikhale PJ. Carboplatin hypersensitivity. Int J Gynecol Cancer 2005; 15:13-18. Comprehensive revue of the value of skin testing and desensitizations in HSR to carboplatin.
34. Choi J, Harnett P, Fulcher DA. Carboplatin desensitization. Ann Allergy Asthma Immunol 2004; 93:137-141.
35. Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 1994; 53:121-122.
36. Goldberg A, Confino-Cohen R, Fishman A, et al. A modified, prolonged desensitization protocol in carboplatin allergy. J Allergy Clin Immunol 1996; 98:841-843.
37. Confino-Cohen R, Fishman A, Altaras M, Goldberg A. Successful carboplatin desensitization in patients with proven carboplatin allergy. Cancer 2005; 104:640-643. Value of desensitization to treat severe, anaphylactic HSR to carboplatin.
38. Markman M, Zanotti K, Kulp B, et al. Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity. Gynecol Oncol 2003; 89:514-516.
39. Zorzou MP, Efstathiou E, Galani E, et al. Carboplatin hypersensitivity reactions: a single institution experience. J Chemother 2005; 17:104-110. Recognition that premedication and slow infusions alone cannot prevent carboplatin HSRs.
40. Rose PG, Fusco N, Smrekar M, et al. Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol 2003; 89:429-433.
41. McElroy TM, Gruenigen VE, Waggoner SE. A case of prolonged carboplatin therapy in a patient with carboplatin hypersensitivity. Gynecol Oncol 2003; 91:435-437.
42. Robinson JB, Singh D, Bodurka-Bevers DC, et al. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 2001; 82:550-558.
43. Kandel MJ, Loehr A, Harter P, et al. Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity. Int J Gynecol Cancer 2005; 15:780-784. Cisplatinum is temporarily tolerated in patients with carboplatin HSRs.
44. Goldberg A, Altaras MM, Mekori YA, et al. Anaphylaxis to cisplatin: diagnosis and value of pretreatment in prevention of recurrent allergic reactions. Ann Allergy 1994; 73:271-272.
45. Maindrault-Goebel F, Andre T, Tournigand C, et al. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 2005; 41:2262-2267. Series of patients with type I HSRs to oxaliplatin.
46. Lenz G, Hacker UT, Kern W, et al. Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution. Anticancer Drugs 2003; 14:731-733.
47. Gammon D, Bhargava P, McCormick MJ. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist 2004; 9: 546-549.
48. Gonzalez-Mahave I, Lobera IT, Blasco SA, et al. Anaphylaxis produced by oxaliplatin. J Investig Allergol Clin Immunol 2005; 15:75-77. Confirmation of anaphylaxis induced by oxaliplatin.
49. Mis L, Fernando NH, Hurwitz HI, Morse MA. Successful desensitization to oxaliplatin. Ann Pharmacother 2005; 39:966-969. Successful desensitization to oxaliplatin - case report.
50. Lim KH, Huang MJ, Lin HC, et al. Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. Anticancer Drugs 2004; 15:605-607.
51. Lafay-Cousin L, Holm S, Qaddoumi I, et al. Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer 2005; 103:2636-2642. Substitution therapy in children with HSRs to carboplatin.
52. Ogle SK, Rose MM, Wildes CT. Development and implementation of a carboplatin desensitization protocol for children with neurofibromatosis, type 1 and hypersensitivity reactions in an outpatient oncology clinic. J Pediatr Oncol Nurs 2002; 19:122-126.
53. Lazzareschi I, Ruggiero A, Riccardi R, et al. Hypersensitivity reactions to carboplatin in children. J Neurooncol 2002; 58:33-37.
54. Broome CB, Schiff RI, Friedman HS. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Med Pediatr Oncol 1996; 26:105-110.
55. Sims-McCallum RP. Outpatient carboplatin desensitization in a pediatric patient with bilateral optic glioma. Ann Pharmacother 2000; 34:477-478.
56. Chavez-Lopez MA, Delgado-Villafana J, Gallaga A, Huerta-Yanez G. Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis. Allergol Immunopathol (Madr) 2005; 33:291-292. Evidence of anaphylactic reaction induced by humanized monoclonal antibody infliximab.
57. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004; 10:333-338.
58. Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol 2003; 14:1792.
59. Allen KP, Funk AJ, Mandrell TD. Toxic epidermal necrolysis in two rhesus macaques (Macaca mulatta) after administration of rituximab. Comp Med 2005; 55:377-381.
60. Leone G, Sica S, Voso MT, et al. Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects. Cardiovasc Hematol Agents Med Chem 2006; 4:33-52.
61. Tada K, Ito Y, Hatake K, et al. Severe infusion reaction induced by trastuzumab: a case report. Breast Cancer 2003; 10:167-169.
62. Janku F, Pribylova O, Zimovjanova M, et al. 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study. Bull Cancer 2004; 91:E279-E283.
63. Cohen AD, Mermershtain W, Geffen DB, et al. Cutaneous photosensitivity induced by paclitaxel and trastuzumab therapy associated with aberrations in the biosynthesis of porphyrins. J Dermatolog Treat 2005; 16:19-21.
64. Nikas SN, Voulgari PV, Drosos AA. Urticaria and angiedema-like skin reactions in a patient treated with adalimumab. Clin Rheumatol 2006; 1-2 [Epub ahead of print].
65. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:711-715.
66. Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med 2006; 30:41-44.
67. Lelong J, Duburque C, Fournier C, et al. Desensitisation to infliximab in patients with Crohn's disease. Rev Mal Respir 2005; 22 (2 Pt 1):239-246. Successful desensitization protocol for HSR to infliximab in Crohn's disease.
68. Stallmach A, Giese T, Schmidt C, et al. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. Eur J Gastroenterol Hepatol 2004; 16:627-630.
69. Melamed J, Stahlman JE. Rapid desensitization and rush immunotherapy to trastuzumab (Herceptin). J Allergy Clin Immunol 2002; 110:813-814.
70. Puchner TC, Kugathasan S, Kelly KJ, Binion DG. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 2001; 7:34-37.